Healthcare Business Rewind: Geron’s GOOD Day, St. Jude’s RESTRUCTURING

Shares of the biotech firm Geron Corporation (NASDAQ:GERN) move up subsequent to Stifel Nicolas starting it off with a Buy and a price target of $4. Earlier in August a SA article reported that Geron’s drugs “have the potential to change the way cancer is treated.” The rating now contributes to the positive chatter surrounding the firm.

Investing Insights: Is Facebook’s Stock a Buy Before Labor Day?

Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals division resolves a dispute with 36 states plus the District of Columbia based upon allegations linked to promotional and marketing practices for its anti-psychotic medication Risperdal. Through the terms, Janssen will pay around $181 million, with pro-rated portions to be paid to each state participating in the settlement.

St. Jude Medical, Inc. (NYSE:STJ) reports plans for restructuring, as it intends to realign its product units into two new operating entities, namely, an Implantable Electronic Systems Division and a Cardiovascular and Ablation Technologies Division. Further, the company will centralize several support functions including information tech, human resources, legal, business development, and various marketing functions.

Don’t Miss: What Are Larry Page and Tim Cook SECRETLY Discussing?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More from The Cheat Sheet